Scoping Review to Map Evidence on Mechanism of Action, Pharmacokinetics, Effectiveness and Side Effects of Centchroman As a Contraceptive Pill

Total Page:16

File Type:pdf, Size:1020Kb

Scoping Review to Map Evidence on Mechanism of Action, Pharmacokinetics, Effectiveness and Side Effects of Centchroman As a Contraceptive Pill Open access Original research BMJ Open: first published as 10.1136/bmjopen-2019-030373 on 7 October 2019. Downloaded from Scoping review to map evidence on mechanism of action, pharmacokinetics, effectiveness and side effects of centchroman as a contraceptive pill Rita Kabra,1 Komal Preet Allagh ,2 Moazzam Ali ,1 Chandani Anoma Jayathilaka,3 Kasonde Mwinga,4 James Kiarie1 To cite: Kabra R, Allagh KP, ABSTRACT Strengths and limitations of this study Ali M, et al. Scoping review to Objective To systematically identify and map the available map evidence on mechanism evidence on effectiveness, side effects, pharmacokinetics ► Strength of our study is that it is the first scoping of action, pharmacokinetics, and mechanism of action of centchroman as a effectiveness and side review to explore the mechanism of action, phar- contraceptive pill. effects of centchroman as a macokinetics, effectiveness and side effects of Introduction Centchroman was introduced in the Indian contraceptive pill. BMJ Open centchroman, when used as a weekly or postcoital national family planning programme in 2016 as a once- 2019;9:e030373. doi:10.1136/ contraceptive pill. bmjopen-2019-030373 a-week short-term contraceptive pill/oral contraceptive. ► A limitation of our review is that we are likely to have At present there are no WHO recommendations on this missed studies on mechanism of action of centchro- ► Prepublication history for method of contraception. We examined the available this paper is available online. man since animal studies were excluded from the evidence through a scoping review. To view these files, please visit review. Methods A search was conducted inclusive to the years the journal online (http:// dx. doi. ► All identified studies in this scoping review were 1970–2019 on electronic databases, grey literature org/ 10. 1136/ bmjopen- 2019- from India. Additionally, roughly half of the studies sources and reference lists of included studies to identify 030373). in this review were published from the developers of studies. The five stages of Arksey and O’Malley’s scoping the drug (Central Drug Research Institute). Received 11 March 2019 review framework were applied in undertaking this ► There is no detailed drug trial on use of centchroman Revised 27 August 2019 scoping review. as a postcoital contraceptive pill. Accepted 02 September 2019 Results The review identified 33 studies conducted ► Studies on side effects of centchroman as a contra- http://bmjopen.bmj.com/ between 1976 and 2017. Two studies reported mechanism ceptive pill are limited by small sample size, short of action of centchroman. Pharmacokinetics was reported duration of follow-up and the fact that all studies by five studies among non-breastfeeding women and have been conducted in India. four studies among breastfeeding women. Eight studies reported on effectiveness ranging from 93% to 100%. Pregnancies due to user failure ranged from 2.6% © Author(s) (or their 1 to 10.2%. Although side effects were reported in 13 oestrogenic or antiestrogenic effects. It employer(s)) 2019. Re-use suppresses the oestrogen receptors in the permitted under CC BY-NC. No studies, the incidence varied greatly between the studies. Continuous bleeding and prolonged cycles >45 days were reproductive organs, but stimulates those commercial re-use. See rights 1 2 on September 27, 2021 by guest. Protected copyright. and permissions. Published by the most commonly reported side effects. All studies of other organs like the bones. It is used BMJ. conducted had a small sample size and the duration of as a contraceptive pill/oral contraceptive 1Department of Reproductive follow-up of women was 12 months or less. Fifty-five per and in treatment of dysfunctional uterine Health and Research, World cent of studies were by the developers of the pill (Central bleeding, mastalgia and fibroadenoma due Health Organization, Geneva, Drug Research Institute) and results of the phase IV clinical to its oestrogen antagonist effect.3 Due to Switzerland trial were unavailable. 2Consultant, World Health its oestrogen agonist effect, centchroman is Conclusions The scoping review shows that studies with used for management of osteoporosis and Organization, Geneva, robust designs and conducted in international context Switzerland its levoisomer has been shown to have some are lacking. Insufficient evidence exists on centchroman 3Department of Family Health, 3 use as a postcoital contraceptive pill. The broad cardioprotective effects. The reported advan- Gender and Life course, World tages of centchroman over other contracep- Health Organization Regional uncertainty in range of side effects and effectiveness in Office for South-East Asia, New the studies implies insufficient evidence to make global tive pill/oral contraceptives are: (1) it is taken Delhi, India recommendations on centchroman that is currently once a week; (2) it does not have any side 4World Health Organization licensed as a contraceptive in India. effects seen with hormonal pills like nausea, Country Office for India, New vomiting and weight gain; (3) it is considered Delhi, India safe for use among breastfeeding women4; Correspondence to INTRODUCTION and (4) it can be taken by women of all ages. Dr Komal Preet Allagh; Centchroman acts as a selective oestrogen In the 1960s, the Government of India called komal. allagh@ gmail. com receptor modulator with tissue selective on Indian laboratories to develop alternate Kabra R, et al. BMJ Open 2019;9:e030373. doi:10.1136/bmjopen-2019-030373 1 Open access BMJ Open: first published as 10.1136/bmjopen-2019-030373 on 7 October 2019. Downloaded from birth control pills. The team at Central Drug Research In this review we have focused on the use of centchroman Institute (CDRI) took up this challenge and synthesised3 5 as an contraceptive pill/oral contraceptive (weekly pill centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-p(β-pyr- and postcoital pill). As a weekly contraceptive pill, the rolidinoethoxy)-phenyl-7-methoxychroman) in recommended dosage of centchroman is a 30 mg pill 1967.3 6 Since it was made at CDRI and belongs to the twice a week for 12 weeks, followed by a 30 mg pill once chroman family, it was named as centchroman. In 1994, a week.4 5 Centchroman as an emergency postcoital pill centchroman was given an international non-proprietary is taken as a 60 mg dose within 72 hours of intercourse.12 7 name as ormeloxifene. Following preclinical and clin- We are conducting this scoping review to determine the ical studies (phase 1 and 2) in 1989 the Drug Controller scope/coverage of the body of literature on effectiveness, General of India approved centchroman as a contracep- safety, pharmacokinetics and mechanism of action of 3 6 tive pill/oral contraceptive in 1991. It was available in centchroman as a contraceptive pill (weekly and postco- the Indian market since 1992. It was first manufactured ital). This review will identify and map the types of avail- by Torrent Pharmaceuticals, Ahmedabad, and marketed able evidence on centchroman as a contraceptive pill and under brand name Centron. Later, Hindustan Latex determine any knowledge gaps. Limited (HLL) Lifecare, Thiruvananthapuram, manu- factured it under the brand names Choice-7 and Saheli.8 Aims and objectives The Ministry of Health and Family Welfare, India, has This scoping review aims to systematically include the distributed centchroman at a subsidised cost since 1995 3 6 entire range of published and grey literature on: (social marketing scheme). ► Extent and type of evidence on effectiveness and side In 2008, HLL Lifecare entered the international market by launching centchroman as a postcoital pill under the effects of using centchroman as a contraceptive pill brand name Ivyfemme in Peru, South America.9 However, (weekly and postcoital pill). in 2010 the licence to sell the pill was revoked by Peru’s ► Extent of evidence on mechanism of action of Directorate General of supplies and drugs. The reason centchroman when used as a contraceptive in women. given for this was that the pill acted by preventing implan- ► Extent of evidence on pharmacokinetics of tation of a fertilised egg and sale of any abortifacient drug centchroman among both non-lactating and breast- was considered illegal in Peru.9 In 2013, HLL Lifecare feeding women. launched centchroman as a postcoital pill in India under METHODS the brand name Tatkal-72.10 The production of Tatkal-72 A protocol for this scoping review was developed a priori was discontinued in 2014 due to restrictions on marketing using the Arksey and O’Malley York’s five-stage frame- and advertising of emergency contraceptive pills in India. work.13 The five steps of the scoping review were: (1) The Ministry of Health and Family Welfare, India, in April 2016 decided to expand oral contraceptive options identifying the research question; (2) identifying the http://bmjopen.bmj.com/ by including centchroman in the national family plan- search strategy; (3) study selection; (4) data charting; and ning programme under the brand name Chhaya.4 5 11 (5) collating, summarising and reporting the results. Chhaya is available to women through the public delivery system free of cost. Oral contraceptives that are safe Step 1: identification of the research question among breastfeeding women have a better potential to This scoping review was conducted to answer the improve the use of family planning methods by post- following primary research question: What is the current partum women, hence centchroman was included in the state of evidence on effectiveness and side effects of centchroman national family planning programme. Figure 1 depicts as a contraceptive pill (weekly pill and postcoital pill)? The on September 27, 2021 by guest. Protected copyright. the key milestones in the evolution of centchroman in secondary research questions were: What is current avail- India. able evidence on mechanism of action of centchroman in women? Figure 1 Key milestones on evolution of centchroman. CDRI, Central Drug Research Institute.
Recommended publications
  • Levosert 20Microgram/24 Hours Intrauterine Delivery System UK/H/3030/001/DC
    PAR Levosert 20microgram/24 hours Intrauterine Delivery System UK/H/3030/001/DC Public Assessment Report Decentralised Procedure LEVOSERT 20MICROGRAM/24 HOURS INTRAUTERINE DELIVERY SYSTEM (levonorgestrel) Procedure No: UK/H/3030/001/DC UK Licence No: PL 30306/0438 ACTAVIS GROUP PTC ehf 1 PAR Levosert 20microgram/24 hours Intrauterine Delivery System UK/H/3030/001/DC LAY SUMMARY Levosert 20 microgram/24 hours Intrauterine Delivery System (levonorgestrel, intrauterine delivery system, 52mg (20 micrograms/24 hours)) This is a summary of the Public Assessment Report (PAR) for Levosert 20 microgram/24 hours Intrauterine Delivery System (PL 30306/0438; UK/H/3030/001/DC, previously PL 34096/0003; UK/H/3030/001/DC). It explains how Levosert 20 microgram/24 hours Intrauterine Delivery System was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use Levosert 20 microgram/24 hours Intrauterine Delivery System. For practical information about using Levosert 20 microgram/24 hours Intrauterine Delivery System, patients should read the package leaflet or contact their doctor or pharmacist. Levosert 20 microgram/24 hours Intrauterine Delivery System may be referred to as Levosert in this report. What is Levosert and what is it used for? Levosert is an intrauterine delivery system (IUS) for insertion in the womb. It can be used in the following ways: • as an effective method of contraception (prevention of pregnancy); • for heavy menstrual bleeding (heavy periods). Levosert is also useful for reducing menstrual blood flow, so it can be used if you suffer from heavy menstrual bleeding (periods).
    [Show full text]
  • F.8 Ethinylestradiol-Etonogestrel.Pdf
    General Items 1. Summary statement of the proposal for inclusion, change or deletion. Here within, please find the evidence to support the inclusion Ethinylestradiol/Etonogestrel Vaginal Ring in the World Health Organization’s Essential Medicines List (EML). Unintended pregnancy is regarded as a serious public health issue both in developed and developing countries and has received growing research and policy attention during last few decades (1). It is a major global concern due to its association with adverse physical, mental, social and economic outcomes. Developing countries account for approximately 99% of the global maternal deaths in 2015, with sub-Saharan Africa alone accounting for roughly 66% (2). Even though the incidence of unintended pregnancy has declined globally in the past decade, the rate of unintended pregnancy remains high, particularly in developing regions. (3) Regarding the use of contraceptive vaginal rings, updated bibliography (4,5,6) states that contraceptive vaginal rings (CVR) offer an effective contraceptive option, expanding the available choices of hormonal contraception. Ethinylestradiol/Etonogestrel Vaginal Ring is a non-biodegradable, flexible, transparent with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. Ethinylestradiol/Etonogestrel Vaginal Ring is intended for women of fertile age. The safety and efficacy have been established in women aged 18 to 40 years. The main advantages of CVRs are their effectiveness (similar or slightly better than the pill), ease of use without the need of remembering a daily routine, user ability to control initiation and discontinuation, nearly constant release rate allowing for lower doses, greater bioavailability and good cycle control with the combined ring, in comparison with oral contraceptives.
    [Show full text]
  • Farr Handouts
    4/14/2021 Recent Pharmacological & Faculty Therapeutic Developments in Women’s Health Glen E. Farr, PharmD Professor Emeritus of Clinical Satellite Conference and Live Webcast Pharmacy and Translational Science April 16, 2021 University of Tennessee 9:00 – 12:00 p.m. Central Time College of Pharmacy [email protected] Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division Educational Objectives Still Have • Outline the recent developments, Sugar & guidelines and/or recommendations Spice for pharmacological management of women’s health conditions, with a focus on contraception. • Identify essential information to counsel patients on the therapeutic application of these medications. Edi the Grand Dog’s first visit to our house 1 4/14/2021 2020 Drug Approvals FDA Annual Novel • 53 Novel agents approved Drug Approvals: – Historical previous 10 year average = 40 2011-2020 • 31 Orphan Drugs • 21 “First in Class” 59 53 48 45 46 • 17 Fast-track 39 41 30 • 22 Break-through 27 22 • 30 Priority review 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 • 12 Accelerated approval FDA.gov Faster FDA Drug Approvals: 3 Question Knowledge Good or Bad? Assessment on • Over the last 4 decades, the FDA has loosened its Contraception requirements for approving new drugs, increasingly accepting less data and more surrogate endpoints in clinical trials, and shortening its reviews. Is this good or bad? • From 1995 to 1997, 80.6% of new drugs were approved on the basis of two pivotal trials — but that number dropped to 52.8% from 2015 to 2017. A number of programs were enacted during the study period that led to faster approvals, such as fast track and the breakthrough therapy designation.
    [Show full text]
  • Agile Patch (AG200-15) October 30, 2019 Agile Therapeutics, Inc
    CO-1 Agile Patch (AG200-15) October 30, 2019 Agile Therapeutics, Inc. Bone, Reproductive, and Urologic Drugs Advisory Committee CO-2 Introduction Geoffrey Gilmore Senior Vice President Agile Therapeutics, Inc. CO-3 Need for More Contraceptive Options to Fit Individual Lifestyles, Evolving Needs . Unintended pregnancy: significant public health problem . Another transdermal system could provide women new, non-invasive method . Data show many women want a contraceptive patch1 . Only available patch delivers ~56 mcg of estrogen . Lower-dose patch benefits women seeking transdermal option Focus on approvability of Agile Patch as that new option 1. IMS National Prescription Audit CO-4 Key Topics for Discussion Topics Points to Consider • Varying definitions of low-dose estrogen 1. Low-dose CHC • Agile Patch delivers ~30 mcg daily of ethinyl estradiol (EE) • Only contraceptive patch available delivers ~56 mcg daily EE • FDA considers an unmet need in terms of serious conditions 2. Unmet Need • Contraception needs defined by gaps in options 3. Prespecified • Contraceptive trials not designed to meet a specific objective Criterion in • Study 23 designed to estimate Pearl Index, regulatory standard for Contraceptive Trials evaluating efficacy with tight confidence interval 4. Pearl Index: Upper • UB ≤ 5 based on historical contraceptive studies Bound of 95% CI • Limited utility for evaluating more contemporary trials, like Study 23 CO-5 Combination Hormonal Contraceptive (CHC) with Levonorgestrel (LNG) + Ethinyl Estradiol (EE) 28 cm2 < 1mm thick
    [Show full text]
  • Recent Advances in Hormonal Contraception HW Raymond Li1 and Richard a Anderson2*
    Published: 09 August 2010 © 2010 Medicine Reports Ltd Recent advances in hormonal contraception HW Raymond Li1 and Richard A Anderson2* Addresses: 1Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, People’s Republic of China; 2Division of Reproductive and Developmental Sciences, The University of Edinburgh, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK * Corresponding author: Richard A Anderson ([email protected]) F1000 Medicine Reports 2010, 2:58 (doi:10.3410/M2-58) This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes. The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/medicine/content/2/58 Abstract This report reviews some of the new studies regarding new hormonal contraceptive formulations (e.g., Yaz, Qlaira®, extended-cycle or continuous combined contraceptives, subcutaneous depot medroxyprogesterone acetate, and ulipristal acetate as an emergency contraceptive). Recent data on the relationship between hormonal contraceptive use and bone health are also reviewed. Introduction and context better than, that of older COCs and has an acceptable Hormonal contraception is one of the most widely used bleeding pattern. Yaz is currently the only COC with contraceptive modalities and provides very good efficacy reported evidence for and approved indication in and low failure rates.
    [Show full text]
  • Contraception - Update and Trends Rabe T J
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie Contraception - Update and Trends Rabe T J. Reproduktionsmed. Endokrinol 2010; 7 (Sonderheft 1), 18-38 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Contraception – Update and Trends Contraception – Update and Trends* T. Rabe Fertility control in the future will focus on the improvement of existing methods (efficacy, side effects, easy use, duration of action, manufacturing process, costs), on new approaches (mode of action) bringing additional health benefits, and on new targets for nonhormonal contraception. Counselling of women in view to contraceptive choices based on the individual risk (e.
    [Show full text]
  • Contraceptive Effectiveness and Obesity
    Contraceptive Effectiveness and Obesity Diana Blithe, PhD Program Director for Contraceptive Development Contraception Research Branch Disclosures: NICHD has a Collaborative Research and Development Agreement (CRADA) with HRA Pharma (Paris, France). The goal of the CRADA is to develop Ulipristal Acetate (CDB-2914) for therapeutic indications. NICHD Principal Investigators: Diana Blithe, PhD & Lynnette Nieman, MD Types of Obesity – Benign vs At-risk • Healthy normal weight - BMI 18.5 - 24.9 kg/m2 0 - 1 metabolic syndrome component: 1) Triglycerides ≥150 mg/dl 2) HDL < 50 mg/dl and/or use of lipid-lowering medication 3) Glucose ≥100 mg/dl 4) Hypertension and/or use of anti-hypertensive medication • As of 2012, ~32% of reproductive age women are obese. Ogden CL et al. Prevalence of Childhood and Adult Obesity in the United States, 2011-2012 . JAMA. 2014;311:806-814 • Benign (Metabolically healthy) obesity - BMI ≥30 kg/m2 0 - 1 metabolic syndrome component (include in contraceptive clinical trials?) • At Risk (Unhealthy) obesity - BMI ≥30 kg/m2 ≥ 2 metabolic syndrome components (exclude from contraceptive clinical trials!) Bleil ME, et al. Pubertal Timing, Androgens, and Obesity Phenotypes in Women at Midlife. J Clin Endocrinol Metab. 2012 97: E1948–52 Midlife for women is age 25-45. Midlife for men? Risk of Venous Thromboembolism: with Hormonal Contraceptives containing Ethinyl Estradiol (EE), with Obesity or with Pregnancy R.R Incidence Young women in general population 1 1- 5 /10,000/y Use of COCs 2.5-5.5* 3-15 /10,000/y Low EE dose COC (BMI 20-25) 2 Low EE dose COC (BMI 30-35) 4 Low EE dose COC (BMI ≥35) 8 Pregnancy: Pregnant Women (BMI ≤25) 12 During Pregnancy 5-20 /10,000/y Post Partum 40-65 /10,000/y Pregnant Women (BMI ≥30) 30 May be a higher PE vs DVT rate in obese pregnant women *de Bastos M, et al .
    [Show full text]
  • Emergency Contraception - Potential for Women’S Health
    Review Article Indian J Med Res 140 (Supplement), November 2014, pp 45-52 Emergency contraception - Potential for women’s health Suneeta Mittal* Department of Obstetrics & Gynecology, All India Institute of Medical Sciences, New Delhi, India Received April 12, 2013 Emergency contraception (EC) is a safe and effective method which is used to prevent unwanted pregnancy after unprotected sexual intercourse. Many of the unwanted pregnancies end in unsafe abortions. The search for an ideal contraceptive, which does not interfere with spontaneity or pleasure of the sexual act, yet effectively controls the fertility, is still continuing. Numerous contraceptive techniques are available, yet contraceptive coverage continues to be poor in India. Thus, even when not planning for a pregnancy, exposure to unprotected sex takes place often, necessitating the use of emergency contraception. This need may also arise due to failure of contraceptive method being used (condom rupture, diaphragm slippage, forgotten oral pills) or following sexual assault. Emergency contraception is an intervention that can prevent a large number of unwanted pregnancies resulting from failure of regular contraception or unplanned sexual activity, which in turn helps in reducing the maternal mortality and morbidity due to unsafe abortions. However, a concern has been expressed regarding repeated and indiscriminate usage of e-pill, currently the rational use of emergency contraception is being promoted as it is expected to make a significant dent in reducing the number of unwanted pregnancies and unsafe abortions. In fact, since the introduction of emergency contraception, the contribution of unsafe abortion towards maternal mortality has declined from 13 to 8 per cent. Key words Emergency contraception - IUD - levonorgestrel - pregnancy - unprotected sex - Yuzpe regimen Introduction signifies, it is meant only for contraceptive emergency situations and not for routine or repeated use.
    [Show full text]
  • NEXPLANON (Etonogestrel Implant)
    Application No. 021529/S11 NEXPLANON (etonogestrel implant) IMPLANON (etonogestrel implant) HIGHLIGHTS OF PRESCRIBING INFORMATION • Insertion and removal complications: Pain, paresthesias, These highlights do not include all the information needed to use bleeding, hematoma, scarring or infection may occur. (5.1) NEXPLANON safely and effectively. See full prescribing • Menstrual bleeding pattern: Counsel women regarding changes in information for NEXPLANON. bleeding frequency, intensity, or duration. (5.2) • Ectopic pregnancies: Be alert to the possibility of an ectopic NEXPLANON (etonogestrel implant) pregnancy in women using NEXPLANON who become pregnant Radiopaque or complain of lower abdominal pain. (5.3) Subdermal Use Only • Thrombotic and other vascular events: The NEXPLANON implant Initial U.S. Approval: 2001 should be removed in the event of a thrombosis. (5.4) • Liver disease: Remove the NEXPLANON implant if jaundice --------------------------- RECENT MAJOR CHANGES --------------------------- occurs. (5.7) Dosage and Administration • Elevated blood pressure: The NEXPLANON implant should be Removal of NEXPLANON (2.3) 08/2015 removed if blood pressure rises significantly and becomes Warnings and Precautions uncontrolled. (5.9) In Situ Broken or Bent Implant (5.16) 08/2015 • Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women using NEXPLANON. (5.11) ----------------------------INDICATIONS AND USAGE ---------------------------- NEXPLANON is a progestin indicated for use by women to prevent ------------------------------
    [Show full text]
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION with implants in pulmonary vessels include chest pain, dyspnea, These highlights do not include all the information needed to use cough, or hemoptysis. Surgical interventions may be necessary to NEXPLANON safely and effectively. See full prescribing remove implants. (5.1) information for NEXPLANON. • Menstrual bleeding pattern: Counsel women regarding changes in bleeding frequency, intensity, or duration. (5.2) NEXPLANON (etonogestrel implant) • Ectopic pregnancies: Be alert to the possibility of an ectopic Radiopaque pregnancy in women using NEXPLANON who become pregnant Subdermal Use Only or complain of lower abdominal pain. (5.3) Initial U.S. Approval: 2001 • Thrombotic and other vascular events: The NEXPLANON implant should be removed in the event of a thrombosis. (5.4) --------------------------- RECENT MAJOR CHANGES --------------------------- • Liver disease: Remove the NEXPLANON implant if jaundice Warnings and Precautions, Complications of Insertion and Removal occurs. (5.7) (5.1) ---------------------------------------- ------------------------------------- 9/2020 • Elevated blood pressure: The NEXPLANON implant should be Warnings and Precautions, Broken or Bent Implant (5.16) ------- 10/2020 removed if blood pressure rises significantly and becomes ----------------------------INDICATIONS AND USAGE ---------------------------- uncontrolled. (5.9) NEXPLANON is a progestin indicated for use by women to prevent • Carbohydrate and lipid metabolic effects: Monitor prediabetic and pregnancy. (1) diabetic women using NEXPLANON. (5.11) ----------------------- DOSAGE AND ADMINISTRATION ----------------------- ------------------------------ ADVERSE REACTIONS ------------------------------ Insert one NEXPLANON subdermally just under the skin at the inner Most common (≥10%) adverse reactions reported in clinical trials were side of the non-dominant upper arm. NEXPLANON must be removed no change in menstrual bleeding pattern, headache, vaginitis, weight later than by the end of the third year.
    [Show full text]
  • CADTH Canadian Drug Expert Committee Recommendation (Final)
    CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) ETONOGESTREL EXTENDED-RELEASE SUBDERMAL IMPLANT (NEXPLANON — MERCK CANADA INC.) Indication: Prevention of pregnancy for up to three years. RECOMMENDATION The CADTH Canadian Drug Expert Committee recommends that etonogestrel extended-release radiopaque subdermal implant should be reimbursed for the prevention of pregnancy for up to three years only if the following condition is met. Condition for Reimbursement Cost should not exceed the negotiated annualized cost of reimbursed comparable long-acting contraceptive options. Service Line: CADTH Drug Reimbursement Recommendation Version: 1.0 Publication Date: October 2020 Report Length: 9 Pages Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • Gynaecology and Perinatology
    Page 35 to 38 Volume 1 • Issue 1 • 2017 Review Article Gynaecology and Perinatology ISSN: 2576-8301 Family Planning and Birth Control in the Developing World: New Opportunities Thanks to Updated Research Kraetschmer K* Austrian American Medical Research Institute, Hermanng 4, A-2700 WrNeustadt, Austria *Corresponding Author: Kraetschmer K, Austrian American Medical Research Institute, Hermanng 4, A-2700 WrNeustadt, Austria. Received: June 07, 2017; Published: July 20, 2017 Abstract On the basis of a steadily-increasing literature on family planning and birth control the paper addresses central questions in the area of contraception in the developing world. Its aim is to describe the possibilities of contraception in regions with limited resources. It draws attention to the most suitable low-cost effective methods of contraception presently available and provides detailed analyses of their efficacy. In concluding it stipulates expansion of their use as well as intensified education on their practicability. Volume 1 Issue 1 July 2017 © All Copy Rights are Reserved by Kraetschmer K. Numerous are the publications and websites on birth control and family planning and even more numerous the data presented in the various statistical analyses. [1] Among the pivotal topics in these studies are unwanted pregnancies, abortion, and maternal mortal- ity ratio, ie, the risk of maternal death per 100.000 livebirths. These issues are a focus of interest not only in public health research but also in socio-economic investigations, and one of the frequently
    [Show full text]